Introduction to pepcid and its role in acid-related disorders
Pepcid, whose active pharmaceutical ingredient is famotidine, belongs to the class of medications known as histamine H2 receptor antagonists. These medications have been a foundation of therapy for acid-related gastrointestinal disorders for several decades, providing effective relief for millions of patients suffering from conditions such as gastroesophageal reflux disease, peptic ulcer disease, and various forms of dyspepsia. Famotidine works by selectively blocking the histamine H2 receptors located on the parietal cells of the gastric mucosa, thereby reducing both basal and stimulated gastric acid secretion. The clinical impact of this class of medications has been substantial, transforming the management of acid-peptic diseases and reducing the need for surgical intervention in conditions that previously required operative treatment.
The development of H2 receptor antagonists represented a major therapeutic advance that built upon fundamental discoveries in gastrointestinal physiology. The identification of histamine as a potent stimulator of gastric acid secretion, followed by the characterization of distinct histamine receptor subtypes, provided the scientific foundation for the rational development of drugs targeting the H2 receptor. Cimetidine, the first H2 receptor antagonist introduced into clinical practice, was followed by ranitidine, famotidine, and nizatidine, each offering incremental improvements in potency, safety, and convenience. Famotidine, in particular, distinguished itself through its high potency, allowing for lower doses and convenient dosing schedules, and its favorable safety profile resulting from its relative lack of interaction with cytochrome P450 enzymes and androgen receptors.
Gastric acid secretion is a complex physiological process regulated by neural, paracrine, and endocrine pathways that converge on the parietal cell, the acid-producing cell of the gastric epithelium. The parietal cell expresses receptors for three major secretagogues: histamine, acting through H2 receptors; acetylcholine, released from vagal nerve endings and acting through muscarinic M3 receptors; and gastrin, released from antral G cells and acting through cholecystokinin-B receptors. These signaling pathways converge on the activation of the hydrogen-potassium ATPase, also known as the proton pump, which is the final common pathway for acid secretion. Histamine, released from enterochromaffin-like cells in response to gastrin and vagal stimulation, is the primary paracrine mediator that amplifies the acid secretory response to other stimuli, making H2 receptor blockade a particularly effective strategy for reducing acid secretion.
Famotidine competitively inhibits the binding of histamine to H2 receptors on the basolateral membrane of parietal cells, thereby attenuating the intracellular signaling cascade that culminates in the activation of the proton pump. The result is a reduction in the volume and concentration of gastric acid secreted in response to all physiological stimuli, including food intake, which is mediated by gastrin release and vagal activation, and nocturnal acid secretion, which is predominantly driven by basal histaminergic tone. The degree of acid suppression achieved with famotidine is dose-dependent, with higher doses producing more deep and sustained reductions in intragastric acidity. This pharmacological profile supports both over-the-counter use for mild, intermittent symptoms and prescription-strength dosing for more severe or persistent acid-related conditions.
Pharmacodynamics and pharmacokinetics
Famotidine exhibits a rapid onset of action following oral administration, with the antisecretory effect becoming apparent within approximately one hour of dosing. The peak effect on gastric acid secretion occurs within one to three hours after oral administration, and the duration of action extends for approximately ten to twelve hours, supporting twice-daily dosing for sustained acid suppression throughout the 24-hour period. The relatively long duration of action distinguishes famotidine from some other H2 receptor antagonists and contributes to its clinical utility in conditions requiring prolonged acid suppression, such as the healing of erosive esophagitis. The pharmacokinetic profile of famotidine involves oral bioavailability of approximately 40 to 45 percent, with absorption not affected by the presence of food in the stomach.
The distribution of famotidine throughout the body reflects its physicochemical properties as a relatively hydrophilic compound with limited penetration into the central nervous system and other tissues protected by cellular barriers. The apparent volume of distribution exceeds total body water, indicating some degree of tissue binding, although the drug is not protein-bound in plasma. Famotidine crosses the blood-brain barrier to a limited extent, which accounts for the lower incidence of central nervous system side effects compared with cimetidine, an earlier H2 receptor antagonist that more readily enters the central nervous system. The limited central nervous system penetration of famotidine is clinically advantageous, particularly in elderly patients who may be more susceptible to the confusion, delirium, and other neuropsychiatric effects that have been associated with H2 receptor antagonist therapy.
Famotidine is eliminated from the body through a combination of renal excretion and hepatic metabolism, with renal elimination of unchanged drug representing the predominant clearance mechanism. Approximately 65 to 70 percent of an orally administered dose is excreted unchanged in the urine, with the remainder undergoing hepatic metabolism to form the pharmacologically inactive sulfoxide metabolite. The elimination half-life of famotidine is approximately 2.5 to 4 hours in patients with normal renal function, but this half-life can be prolonged in patients with impaired renal function. Consequently, dose adjustment is recommended for patients with moderate to severe renal impairment to prevent the accumulation of the drug and the associated risk of dose-related adverse effects. The strong dependence on renal elimination also means that drug interactions mediated by the inhibition of hepatic drug-metabolizing enzymes are minimal, representing another advantage of famotidine over cimetidine.
- Gastric acid suppression: Famotidine reduces both basal acid secretion and secretion stimulated by food, pentagastrin, insulin, caffeine, and betazole, with a single 20 mg dose reducing basal acid secretion by approximately 70 to 90 percent over a 10-hour period.
- Pepsin output reduction: In addition to reducing acid secretion, famotidine decreases pepsin output proportionally to the reduction in gastric volume, contributing to the overall reduction in the peptic activity of gastric secretions.
- Gastric mucosal protection: Indirect protective effects on the gastric and duodenal mucosa result from the reduction in acid and pepsin exposure, allowing endogenous mucosal defense mechanisms to promote healing of acid-related mucosal injury.
Clinical indications and therapeutic applications
Pepcid is indicated for the treatment and prevention of a spectrum of acid-related gastrointestinal disorders that vary in severity from mild, intermittent symptoms to chronic, erosive disease. Gastroesophageal reflux disease, commonly referred to as GERD, is one of the most prevalent indications for famotidine therapy. This condition involves the abnormal reflux of gastric contents into the esophagus, producing symptoms that include heartburn, regurgitation, and in more severe cases, dysphagia and chest pain. The pathophysiology of GERD involves dysfunction of the lower esophageal sphincter, impaired esophageal clearance of refluxed material, and delayed gastric emptying, all of which contribute to prolonged contact between the esophageal mucosa and acidic gastric contents. By reducing the acidity and volume of gastric secretions, famotidine decreases the injurious potential of the refluxate and promotes healing of reflux-induced esophageal injury.
Over-the-counter formulations of famotidine are indicated for the short-term relief of heartburn, acid indigestion, and sour stomach in patients with mild, intermittent symptoms. These products are appropriate for self-medication by patients whose symptoms are occasional, predictable, and responsive to episodic acid suppression. Over-the-counter famotidine can be used for the prevention of meal-related or activity-related heartburn when taken shortly before the anticipated trigger, providing a convenient option for patients who experience predictable symptom exacerbations. However, patients whose symptoms persist or worsen despite appropriate over-the-counter therapy, or those who experience alarm symptoms such as dysphagia, odynophagia, unintentional weight loss, or gastrointestinal bleeding, should seek medical evaluation to exclude more serious underlying pathology and to consider prescription-strength acid suppression or alternative diagnostic and therapeutic approaches.
Peptic ulcer disease, encompassing both gastric and duodenal ulcers, is another major indication for famotidine therapy. Peptic ulcers result from an imbalance between aggressive factors, primarily gastric acid and pepsin, and defensive factors, including the mucus-bicarbonate barrier, mucosal blood flow, and epithelial restitution mechanisms. While the recognition of Helicobacter pylori infection and the use of nonsteroidal anti-inflammatory drugs as the predominant etiologies of peptic ulcer disease has shifted treatment paradigms, acid suppression remains an important component of ulcer management. Famotidine promotes ulcer healing by reducing the acid load on the ulcerated mucosa, thereby facilitating the natural processes of granulation tissue formation and re-epithelialization that are essential for ulcer resolution.
Zollinger-ellison syndrome and pathological hypersecretory conditions
Zollinger-Ellison syndrome is a rare but clinically important indication for famotidine therapy that requires higher doses than those used for routine acid-related disorders. This syndrome is caused by a gastrin-secreting neuroendocrine tumor, most commonly located in the duodenum or pancreas, that produces uncontrolled hypergastrinemia. Elevated circulating gastrin levels drive excessive gastric acid secretion through chronic stimulation of the parietal cells, resulting in severe peptic ulcer disease, often affecting atypical locations such as the distal duodenum and jejunum, and chronic diarrhea due to the volume of acid entering the small intestine and inactivating pancreatic enzymes. The deep acid hypersecretion characteristic of Zollinger-Ellison syndrome requires aggressive acid suppression to control symptoms, promote ulcer healing, and prevent complications such as hemorrhage and perforation.
The doses of famotidine required for adequate acid suppression in Zollinger-Ellison syndrome may be several times higher than standard therapeutic doses, and the dosing frequency may need to be increased to every six to eight hours to maintain adequate acid control throughout the day. While proton pump inhibitors have largely supplanted H2 receptor antagonists as first-line therapy for acid suppression in Zollinger-Ellison syndrome due to their more potent and sustained effect, famotidine may still affect patients who cannot tolerate proton pump inhibitors or as an adjunct to proton pump inhibitor therapy in patients with refractory acid hypersecretion. The management of Zollinger-Ellison syndrome requires a multidisciplinary approach involving gastroenterology, endocrinology, and surgical oncology specialists to address both the consequences of acid hypersecretion and the underlying neoplastic process.
Other pathological hypersecretory conditions, including systemic mastocytosis and basophilic leukemia, may also require high-dose famotidine therapy to control the consequences of excessive histamine production on gastric acid secretion. In systemic mastocytosis, the abnormal proliferation and activation of mast cells leads to the release of histamine and other mediators that can produce symptoms in multiple organ systems, including the gastrointestinal tract. The gastric acid hypersecretion resulting from elevated circulating histamine levels can cause peptic ulcer disease and diarrhea that respond to H2 receptor blockade. Similarly, in basophilic leukemia, the production of histamine by neoplastic basophils can drive excessive acid secretion. In both conditions, famotidine therapy is one component of a comprehensive treatment strategy that must also address the underlying hematologic disorder.
Dosage forms and administration
Pepcid is available in several dosage forms to accommodate different clinical scenarios and patient preferences. Oral tablets containing 10 milligrams and 20 milligrams of famotidine are available both over the counter and by prescription, with the over-the-counter formulations typically limited to the lower dose for short-term use. The prescription-strength 40-milligram tablet is available for more severe acid-related conditions or for the management of pathological hypersecretory states requiring higher doses. An oral suspension formulation is available for patients who have difficulty swallowing tablets, including pediatric patients, elderly patients with dysphagia, and patients with esophageal strictures or other conditions that impede tablet ingestion. An injectable formulation is available for hospitalized patients who cannot take oral medications or who require rapid acid suppression.
The dosing of famotidine varies according to the specific indication being treated, the severity of the condition, and the individual patient’s response to therapy. For the acute treatment of gastroesophageal reflux disease, a typical regimen involves famotidine 20 milligrams taken twice daily for a period of six to twelve weeks, depending on the severity of esophageal injury and the rate of symptomatic and endoscopic improvement. For maintenance therapy following initial healing, a single 20-milligram dose at bedtime may be sufficient to maintain remission in patients with mild to moderate disease. For the healing of active duodenal ulcers, a 40-milligram dose taken once daily at bedtime or 20 milligrams taken twice daily is the standard regimen, with treatment continuing for four to eight weeks. The once-daily dosing at bedtime takes advantage of the importance of suppressing nocturnal acid secretion for ulcer healing.
For over-the-counter use for mild heartburn and acid indigestion, the recommended dose is 10 to 20 milligrams taken approximately 15 to 60 minutes before meals that are anticipated to provoke symptoms, or as directed by the product labeling. The maximum over-the-counter dose is 20 milligrams per day, and the duration of self-treatment should not exceed two weeks without medical consultation. Patients should be advised that over-the-counter famotidine is not intended for the treatment of severe or persistent symptoms, and that symptoms persisting beyond two weeks of appropriate therapy warrant medical evaluation. This restriction on the duration of self-treatment reflects importance of excluding more serious conditions that may present with symptoms similar to those of benign acid-related disorders.
Special populations and dose adjustments
Renal impairment affects the pharmacokinetics of famotidine due to the drug’s extensive renal elimination. In patients with moderate renal impairment, reflected by a creatinine clearance between 30 and 50 milliliters per minute, dose reduction or extension of the dosing interval may be appropriate to prevent drug accumulation and minimize the risk of dose-related adverse effects. For patients with severe renal impairment, characterized by a creatinine clearance below 30 milliliters per minute, the recommended dose of famotidine is reduced to 10 milligrams once daily, or 20 milligrams every 36 to 48 hours depending on the indication. For patients receiving hemodialysis, famotidine is partially removed by the dialysis procedure, and supplemental dosing is not routinely required if the regular dosing schedule is maintained. Patients with hepatic impairment generally do not require dose adjustment, as hepatic metabolism is a minor elimination pathway for famotidine and hepatic dysfunction does not alter drug clearance.
Elderly patients may exhibit altered pharmacokinetics of famotidine due to the age-related decline in renal function that occurs even in the absence of clinically recognized renal disease. While formal dose adjustment based solely on age is not required, elderly patients should be monitored for evidence of dose-related adverse effects, including central nervous system effects such as confusion, dizziness, and hallucinations, which have been reported more frequently in older patients receiving H2 receptor antagonists. The relationship between age and susceptibility to H2 receptor antagonist-related adverse effects may reflect both pharmacokinetic factors, including reduced drug clearance, and pharmacodynamic factors, including increased sensitivity of the aging brain to the central nervous system effects of these medications.
Pediatric dosing of famotidine has been established for certain indications, including the treatment of gastroesophageal reflux disease and peptic ulcer disease in children. The dosing in pediatric patients is typically weight-based, with a recommended dose of 0.5 to 1 milligram per kilogram per day administered in two divided doses. Safety and efficacy data for famotidine in pediatric populations are more limited than in adults, and the decision to use this medication in children should be made in consultation with a pediatric gastroenterologist or other healthcare provider experienced for acid-related disorders in the pediatric population. The availability of an oral suspension formulation facilitates weight-based dosing in children who cannot swallow tablets.
Safety profile and adverse effects
Famotidine is generally well tolerated, with a safety profile that has been characterized through extensive clinical trial experience and decades of post-marketing surveillance. The incidence of adverse effects in clinical trials has been comparable to that observed with placebo, and serious adverse reactions are uncommon. The most frequently reported side effects include headache, occurring in approximately 4 to 5 percent of treated patients, and gastrointestinal symptoms including constipation, diarrhea, and nausea. These side effects are typically mild and self-limited, generally not requiring discontinuation of therapy. The favorable safety profile of famotidine has contributed to its widespread use, including its availability as an over-the-counter medication, and supports its position as a well-tolerated option for patients requiring acid suppression therapy.
The central nervous system effects of H2 receptor antagonists have received particular attention because these medications can cross the blood-brain barrier to varying degrees and may affect central histaminergic neurotransmission. Histamine functions as a neurotransmitter in the central nervous system, where it plays roles in regulating arousal, cognition, and appetite. Cimetidine, an earlier H2 receptor antagonist, was associated with a range of central nervous system effects including confusion, hallucinations, and delirium, particularly in elderly patients, those with renal or hepatic impairment, and patients receiving high intravenous doses. Famotidine, which penetrates the blood-brain barrier to a lesser extent than cimetidine, has been associated with a lower incidence of central nervous system side effects, although these effects have been reported in isolated cases, particularly in patients with significant renal impairment leading to elevated plasma drug concentrations.
Hematological effects of famotidine have been reported rarely and include thrombocytopenia, agranulocytosis, and pancytopenia. These effects are idiosyncratic and do not appear to be dose-related, suggesting an immunological or hypersensitivity mechanism rather than direct bone marrow toxicity. The low frequency of these events, combined with the lack of a consistent temporal relationship between drug exposure and the development of cytopenias, makes it difficult to definitively establish causality in individual cases. Patients who develop unexplained fever, sore throat, easy bruising, or bleeding while taking famotidine should undergo hematological evaluation, and the medication should be discontinued if blood dyscrasias are confirmed.
Hepatic effects and drug-induced liver injury
Hepatic effects of famotidine have been reported in post-marketing experience, with cases of cholestatic jaundice, hepatitis, and hepatic enzyme elevations described in the medical literature. The mechanism of famotidine-associated hepatic injury is not well established but may involve an idiosyncratic hypersensitivity reaction rather than direct hepatotoxicity. The latency period between drug initiation and the development of hepatic abnormalities is variable, and the pattern of liver enzyme elevation is typically mixed, with features of both hepatocellular injury and cholestasis. In most reported cases, the hepatic abnormalities resolved following discontinuation of famotidine, although cases of prolonged cholestasis have been described. The rarity of clinically significant hepatic injury in the widespread use of famotidine indicates that the risk to the general population is extremely low, and routine hepatic monitoring is not required for patients taking this medication.
Endocrine effects of H2 receptor antagonists have been most studied for cimetidine, which has been shown to bind to androgen receptors and inhibit the metabolism of estradiol, leading to gynecomastia in men and galactorrhea in women with prolonged high-dose therapy. Famotidine has minimal affinity for androgen receptors and does not affect estradiol metabolism, which accounts for the virtual absence of antiandrogenic effects with this agent. The lack of endocrine effects is a meaningful advantage of famotidine over cimetidine, particularly for male patients requiring long-term acid suppression and for patients with conditions such as breast cancer in whom hormonal manipulation should be avoided. The high receptor selectivity of famotidine for the H2 receptor, with minimal interactions with other receptor systems, contributes to its clean side effect profile relative to earlier generations of H2 receptor antagonists.
Cardiovascular effects of famotidine have been reported rarely, with isolated cases of hypotension, bradycardia, and atrioventricular block described in the literature, primarily in intravenous administration. These effects may relate to the presence of H2 receptors in the cardiovascular system, where histamine exerts complex effects on cardiac contractility, heart rate, and vascular tone. However, the clinical significance of these observations is limited by the rarity of cardiovascular events and the absence of a consistent pattern that would suggest a strong causal relationship. For the most patients, famotidine can be used without concern for adverse cardiovascular effects, including patients with pre-existing cardiovascular disease for whom other medications may pose greater theoretical or practical risks.
Drug interactions and clinical considerations
Famotidine differs importantly from cimetidine in its minimal effects on the cytochrome P450 enzyme system, which accounts for the reduced potential for drug interactions. Cimetidine is a potent inhibitor of CYP1A2, CYP2C9, CYP2D6, and CYP3A4, leading to clinically significant interactions with many medications that are metabolized by these enzymes, including warfarin, theophylline, phenytoin, and certain benzodiazepines. Famotidine, in contrast, does not inhibit cytochrome P450 enzymes at therapeutic concentrations, and the clinically relevant drug interactions associated with famotidine are limited to those mediated by its effect on gastric pH rather than by pharmacokinetic enzyme inhibition.
The effect of famotidine on gastric pH can influence the absorption of certain medications whose bioavailability depends on gastric acidity. Ketoconazole and itraconazole, antifungal agents that require an acidic gastric environment for optimal dissolution and absorption, may exhibit reduced bioavailability when administered concurrently with famotidine. Similarly, atazanavir, a protease inhibitor used in the treatment of human immunodeficiency virus infection, has absorption that is critically dependent on gastric acidity, and the concomitant use of acid-suppressing medications can reduce atazanavir plasma concentrations, potentially compromising antiviral efficacy. For patients requiring both an acid-suppressing medication and a pH-dependent drug, strategies such as administering the medications several hours apart, using alternative antifungals with better absorption profiles, or selecting different antiviral regimens can mitigate the clinical impact of this interaction.
Cephalosporin antibiotics and other medications whose absorption is enhanced by an acidic gastric environment may similarly be affected by famotidine co-administration. Conversely, the absorption of certain medications, such as digoxin, may be increased when gastric acidity is reduced, although the clinical significance of this effect is generally modest. The interaction between acid-suppressing medications and levothyroxine, which requires an acidic environment for optimal dissolution and absorption, has received recent attention, and patients on chronic famotidine therapy who also take levothyroxine may require monitoring of thyroid function and possible dose adjustment of their thyroid hormone replacement. Separating the administration of famotidine and levothyroxine by several hours may help mitigate this interaction, although the prolonged duration of gastric acid suppression achieved with famotidine may limit the effectiveness of this strategy.
Potential interactions between famotidine and antiplatelet medications, particularly clopidogrel, have been investigated in concerns about interactions between clopidogrel and proton pump inhibitors. Clopidogrel, a prodrug that requires CYP2C19-mediated bioactivation, can be affected by CYP2C19 inhibitors, leading to reduced formation of the active metabolite and potentially diminished antiplatelet efficacy. Proton pump inhibitors, particularly omeprazole and esomeprazole, have been shown to inhibit CYP2C19 and reduce clopidogrel activation, prompting regulatory warnings about this combination. Famotidine, which does not inhibit CYP2C19, does not share this interaction, making it a preferable option for acid suppression in patients receiving clopidogrel or other CYP2C19-dependent medications. This difference shows the clinical importance of selecting acid-suppressing therapy based on the patient’s complete medication profile.
Interactions with food and nutritional supplements
The interaction between acid-suppressing medications and vitamin B12 absorption has been recognized as a potential concern with long-term acid suppression therapy. Gastric acid plays an important role in the release of vitamin B12 from dietary proteins, and prolonged suppression of gastric acidity can theoretically impair the absorption of protein-bound vitamin B12, although the absorption of unbound vitamin B12 from supplements is generally preserved. Large population-based studies have suggested an association between long-term use of acid-suppressing medications and an increased risk of vitamin B12 deficiency, although the absolute risk appears to be low. Patients receiving long-term famotidine therapy, particularly those with additional risk factors for vitamin B12 deficiency such as advanced age, vegetarian diet, or a history of gastric surgery, should be monitored for clinical or laboratory evidence of vitamin B12 deficiency. Periodic measurement of vitamin B12 levels may be appropriate in high-risk patients on chronic therapy.
Calcium absorption and bone metabolism represent additional considerations in long-term acid suppression. While concerns about fracture risk have been most prominently associated with proton pump inhibitors, some epidemiological studies have suggested a possible association between H2 receptor antagonist use and fracture risk, although the data are less consistent than for proton pump inhibitors. The proposed mechanism involves reduced calcium absorption in the setting of increased gastric pH, potentially leading to compensatory increases in parathyroid hormone secretion and increased bone resorption. The clinical significance of this potential interaction remains uncertain, and the absolute risk of fracture attributable to H2 receptor antagonist use, if present, appears to be small. Patients with pre-existing risk factors for osteoporosis may benefit from monitoring of bone mineral density and calcium and vitamin D supplementation when long-term famotidine therapy is required.
Food intake can affect the duration and timing of famotidine’s antisecretory effect, which has implications for the optimal timing of doses. While the absorption of famotidine is not affected by food, the presence of food in the stomach stimulates acid secretion through gastrin release and vagal activation, which may partially counteract the antisecretory effect of the medication. For patients using famotidine for the prevention of meal-related heartburn, taking the medication 15 to 60 minutes before a meal allows the drug to achieve effective receptor occupancy before the meal-stimulated acid secretory response begins. For patients with nocturnal symptoms, bedtime dosing provides optimal coverage of the overnight period when basal acid secretion predominates and the gastroprotective effect of food-related buffering is absent. Patient education regarding the optimal timing of famotidine doses relative to meals and sleep can enhance the therapeutic response and improve symptom control.
Therapeutic positioning and comparative efficacy
Famotidine has an important position in the therapeutic options for acid-related disorders, occupying a middle ground between antacids, which provide prompt but short-lived relief, and proton pump inhibitors, which offer more deep and sustained acid suppression. This therapeutic positioning reflects pharmacological profile of H2 receptor antagonists: they act more rapidly than proton pump inhibitors but provide less complete acid suppression, and their effect is sustained longer than antacids but does not match the 24-hour control achievable with proton pump inhibitors. The choice among these therapeutic options should be individualized based on the severity and pattern of symptoms, the underlying pathophysiology of the condition, patient preferences, and considerations of cost and accessibility.
For mild, intermittent heartburn and dyspepsia, famotidine provides an appropriate level of acid suppression with a rapid onset of action that corresponds well to the episodic nature of these symptoms. The availability of over-the-counter famotidine products makes this medication accessible for self-management of mild acid-related symptoms, consistent with the principles of patient empowerment and appropriate self-care. For more severe or persistent symptoms, erosive esophagitis, or other complications of acid reflux, proton pump inhibitors are generally preferred due to their superior acid suppression and higher rates of mucosal healing. However, famotidine may still affect these scenarios as an adjunct to proton pump inhibitor therapy, particularly for the management of breakthrough nighttime symptoms that persist despite optimal proton pump inhibitor dosing.
The role of famotidine in Helicobacter pylori eradication regimens has diminished since the recognition that proton pump inhibitors provide superior acid suppression that enhances the efficacy of antibiotic therapy for this infection. Current guidelines for Helicobacter pylori eradication recommend proton pump inhibitor-based triple or quadruple therapy, with H2 receptor antagonists such as famotidine being reserved for use as a component of backup or alternative regimens. However, famotidine may be useful for symptom management after successful Helicobacter pylori eradication, as the normalization of gastric acid secretion that follows the resolution of the infection can sometimes be associated with a temporary increase in acid-related symptoms that responds to H2 receptor antagonist therapy.